Back to top
more

Bristol Myers Squibb Company (BMY)

(Delayed Data from NYSE)

$60.03 USD

60.03
7,893,261

-0.61 (-1.01%)

Updated Oct 21, 2020 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.44%
2Buy17.91%
3Hold9.42%
4Sell4.91%
5Strong Sell1.79%
S&P50010.66%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (180 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for BMY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Bristol Myers Squibb Company falls in the month of December.

All items in Millions except Per Share data.

12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Assets          
Cash & Equivalents 15,393 8,884 6,812 6,350 4,270
Receivables 7,685 5,965 6,300 5,543 4,299
Notes Receivable 0 0 0 0 0
Inventories 4,293 1,195 1,166 1,241 1,221
Other Current Assets 1,983 1,116 576 570 625
Total Current Assets 29,354 17,160 14,854 13,704 10,415
Net Property & Equipment 6,252 5,027 5,001 4,980 4,412
Investments & Advances 767 1,775 2,480 2,719 4,660
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 510 1,371 1,610 2,996 2,844
Intangibles 86,457 7,629 8,073 8,260 8,300
Deposits & Other Assets 6,604 2,024 1,533 1,048 1,117
Total Assets 129,944 34,986 33,551 33,707 31,748
Liabilities & Shareholders Equity 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Notes Payable 0 0 0 0 0
Accounts Payable 2,445 1,892 2,248 1,664 1,565
Current Portion Long-Term Debt 3,346 1,703 987 992 139
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 6,489 6,014 5,271 4,083
Income Taxes Payable 0 398 231 152 572
Other Current Liabilities 12,513 172 83 762 1,658
Total Current Liabilities 18,304 10,654 9,563 8,841 8,017
Mortgages 0 0 0 0 0
Deferred Taxes/Income 6,454 3,511 4,002 1,520 1,328
Convertible Debt 0 0 0 0 0
Long-Term Debt 43,387 5,646 6,975 5,716 6,550
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 10,101 1,048 1,164 1,283 1,429
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 78,246 20,859 21,704 17,360 17,324
Shareholders Equity 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Preferred Stock 0 0 0 0 0
Common Stock (Par) 292 221 221 221 221
Capital Surplus 43,709 2,081 1,898 1,725 1,459
Retained Earnings 34,474 34,065 31,160 33,513 31,613
Other Equity -1,420 -2,666 -2,183 -2,333 -2,310
Treasury Stock 25,357 19,574 19,249 16,779 16,559
Total Shareholder's Equity 51,698 14,127 11,847 16,347 14,424
Total Liabilities & Shareholder's Equity 129,944 34,986 33,551 33,707 31,748
Total Common Equity 51,698 14,127 11,847 16,347 14,424
Shares Outstanding 2,228.00 1,632.40 1,636.70 1,671.20 1,668.20
Book Value Per Share 23.20 8.65 7.24 9.78 8.65

Fiscal Year End for Bristol Myers Squibb Company falls in the month of December.

All items in Millions except Per Share data.

9/30/2020 6/30/2020 3/31/2020 12/31/2019 9/30/2019
Assets          
Cash & Equivalents NA 21,658 18,322 15,393 32,542
Receivables NA 7,855 8,290 7,685 5,510
Notes Receivable NA 0 0 0 0
Inventories NA 2,384 2,836 4,293 1,192
Other Current Assets NA 2,446 2,405 1,983 947
Total Current Assets NA 34,343 31,853 29,354 40,191
Net Property & Equipment NA 5,777 6,112 6,252 4,830
Investments & Advances NA 523 651 767 925
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 1,088 605 510 1,624
Intangibles NA 79,749 84,118 86,457 7,515
Deposits & Other Assets NA 6,596 5,946 6,604 2,348
Total Assets NA 128,076 129,285 129,944 57,433
Liabilities & Shareholders Equity 9/30/2020 6/30/2020 3/31/2020 12/31/2019 9/30/2019
Notes Payable NA 0 0 0 0
Accounts Payable NA 2,852 3,069 2,445 1,888
Current Portion Long-Term Debt NA 4,819 3,862 3,346 569
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 8,032
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 15,750 12,301 12,513 0
Total Current Liabilities NA 23,421 19,232 18,304 10,489
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 6,157 6,531 6,454 2,919
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 41,853 42,844 43,387 24,390
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 10,701 10,101 1,881
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 78,916 79,308 78,246 39,679
Shareholders Equity 9/30/2020 6/30/2020 3/31/2020 12/31/2019 9/30/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 292 292 292 221
Capital Surplus NA 44,444 43,254 43,709 2,206
Retained Earnings NA 31,565 32,671 34,474 36,555
Other Equity NA -1,490 -1,483 -1,420 -1,357
Treasury Stock NA 25,651 24,757 25,357 19,871
Total Shareholder's Equity NA 49,160 49,977 51,698 17,754
Total Liabilities & Shareholder's Equity NA 128,076 129,285 129,944 57,433
Total Common Equity 0 49,160 49,977 51,698 17,754
Shares Outstanding 2,262.60 2,262.60 2,262.60 2,228.00 1,629.20
Book Value Per Share 0.00 21.73 22.09 23.20 10.90